Conditions: Lymphoma, B-Cell
Keywords: Diffuse large b-cell lymphoma inotuzumab ozogamicin autologous stem cell transplant
Allocation: NON_RANDOMIZED | Intervention model: 
Enrollment: 64
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.

Detailed description:

Arms:
arm 1: Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).

Interventions: intervention 1: inotuzumab ozogamicin (CMC-544) intervention 2: rituximab
Intervention descriptions: intervention 1: 1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses intervention 2: 375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses

Protocol document: